I. Introduction: Multileveled Regulation of the Human Cholinesterase Genes and Their Protein Products

2015 ◽  
pp. 1-11 ◽  
Keyword(s):  
Human Cholinesterase

Schweres Wasser (D2O) als Protektivum proteinhaltiger Arzneimittel. Beispiel: humane Cholinesterase/Protein Drugs Stabilized by Heavy Water (D2O). For Example: Human Cholinesterase

1991 ◽  
Vol 46 (9-10) ◽  
pp. 789-793 ◽  
Author(s):  
Ch. Heyde ◽  
M. Wenzel
Keyword(s):  
Protective Effect ◽  
Heavy Water ◽  
Protein Drugs ◽  
Acid Denaturation ◽  
Individual Effects ◽  
The Individual ◽  
Human Cholinesterase

Abstract Looking for a possible protective effect of heavy water on proteins, cholinesterase and lac­tate dehydrogenase in combination with D2O and further protective substances were exposed to a temperature of 60 °C (for 10 min) and about 45 °C (for several days). In combination with glycerine there resulted an additive protective effect; with NaCl and/or albumin being added the individual effects raised to a higher level. In the cold D2O protects cholinesterase only against acid denaturation, but in combination with warmth also against basic denaturation.

Chimeric Human Cholinesterase

1993 ◽  
Vol 234 (2) ◽  
pp. 289-296 ◽  
Author(s):  
Yael Loewenstein ◽  
Averell Gnatt ◽  
Lewis F. Neville ◽  
Hermona Soreq
Keyword(s):  
Human Cholinesterase

scholarly journals Brain cDNA clone for human cholinesterase.

1987 ◽  
Vol 84 (19) ◽  
pp. 6682-6686 ◽  
Author(s):  
C. McTiernan ◽  
S. Adkins ◽  
A. Chatonnet ◽  
T. A. Vaughan ◽  
C. F. Bartels ◽  
...  
Keyword(s):  
Cdna Clone ◽  
Human Cholinesterase

Successive organophosphate inhibition and oxime reactivation reveals distinct responses of recombinant human cholinesterase variants

1995 ◽  
Vol 31 (1-2) ◽  
pp. 101-110 ◽  
Author(s):  
Mikael Schwarz ◽  
Yael Loewenstein-Lichtenstein ◽  
David Glick ◽  
Jian Liao ◽  
Bent Norgaard-Pedersen ◽  
...  
Keyword(s):  
Human Cholinesterase

Taxodione and Extracts from Salvia austriaca Roots as Human Cholinesterase Inhibitors

2015 ◽  
Vol 30 (2) ◽  
pp. 234-242 ◽  
Author(s):  
Łukasz Kuźma ◽  
Halina Wysokińska ◽  
Joanna Sikora ◽  
Paulina Olszewska ◽  
Elżbieta Mikiciuk-Olasik ◽  
...  
Keyword(s):  
Cholinesterase Inhibitors ◽  
Human Cholinesterase

Tacrine based human cholinesterase inhibitors: Synthesis of peptidic-tethered derivatives and their effect on potency and selectivity

2008 ◽  
Vol 18 (19) ◽  
pp. 5213-5216 ◽  
Author(s):  
Stefania Butini ◽  
Egeria Guarino ◽  
Giuseppe Campiani ◽  
Margherita Brindisi ◽  
Salvatore Sanna Coccone ◽  
...  
Keyword(s):  
Cholinesterase Inhibitors ◽  
Human Cholinesterase

Pharmacokinetics and Pharmacodynamics of Mivacurium in Patients Phenotypically Homozygous for the Atypical Plasma Cholinesterase Variant

2005 ◽  
Vol 102 (6) ◽  
pp. 1124-1132 ◽  
Author(s):  
Doris Østergaard ◽  
Jørgen Viby-Mogensen ◽  
Søren N. Rasmussen ◽  
Mona R. Gätke ◽  
France Varin
Keyword(s):  
Neuromuscular Block ◽  
Elimination Rate ◽  
Plasma Cholinesterase ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Duration Of Action ◽  
First Response ◽  
Train Of Four ◽  
The Times ◽  
Human Cholinesterase ◽  
Different Levels

Background In patients homozygous for atypical plasma cholinesterase, mivacurium causes a long-lasting neuromuscular block, but injection of human cholinesterase has been proven effective in antagonizing the block. The purpose of this study was to evaluate the pharmacodynamics and pharmacokinetics of mivacurium in such patients, as well as the effect of cholinesterase injected early or late after mivacurium. Methods Eleven patients phenotypically homozygous for the atypical variant received 0.075 mg/kg (1 patient) or 0.15 mg/kg (10 patients) mivacurium. The neuromuscular block was monitored using train-of-four nerve stimulation and mechanomyography. Cholinesterase, 2.8-10.0 mg/kg, was administered approximately 30 or 120 min after mivacurium. The times to different levels of neuromuscular recovery and the venous concentrations of the isomers of mivacurium were measured. Results Injection of cholinesterase increased plasma cholinesterase activity to normal and the clearances of the active isomers and the elimination rate constants by a factor of 10-15. The first response was seen in 13.5 min (3.7-44.2 min). Time to a train-of-four ratio of 0.8 ranged from 30 to 60 min (n = 6). Neostigmine injected after cholinesterase shortened recovery further, and a train-of-four ratio of 0.8 was reached in 10-30 min. Conclusion As expected, the duration of action of mivacurium is markedly prolonged in homozygous atypical patients. Injection of cholinesterase significantly increases the metabolism of mivacurium, leading to a shorter duration of action. Injection of neostigmine after the administration of cholinesterase speeds up recovery.

Sign in / Sign up

Export Citation Format

Share Document